Advanced search
1 file | 1.28 MB Add to list

Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer : a systematic review

(2021) GYNECOLOGIC ONCOLOGY. 160(2). p.633-642
Author
Organization
Abstract
Ovarian cancer is often diagnosed in an advanced stage and is associated with a high mortality rate. It is assumed that early detection of ovarian cancer could improve patient outcomes. Unfortunately, effective screening methods for early diagnosis of ovarian cancer are still lacking. Extracellular RNAs circulating in human biofluids can reliably be measured and are emerging as potential biomarkers in cancer. In this systematic review, we present 75 RNA biomarkers detectable in human biofluids that have been studied for early diagnosis of ovarian cancer. The majority of these markers are microRNAs identified using RT-qPCR or microarrays in blood-based fluids. A handful of studies used RNA-sequencing and explored alternative fluids, such as urine and ascites. Candidate RNA biomarkers that were more abundant in biofluids of ovarian cancer patients compared to controls in at least two independent studies include miR-21, the miR-200 family, miR-205, miR-10a and miR-346. Amongst the markers confirmed to be lower in at least two studies are miR-122, miR-193a, miR-223, miR-126 and miR-106b. While these biomarkers show promising diagnostic potential, further validation is required before implementation in routine clinical care. Challenges related to biomarker validation and reflections on future perspectives to accelerate progress in this field are discussed.
Keywords
Obstetrics and Gynaecology, Oncology, RNA, Transcriptomics, Diagnostic biomarkers, Ovarian cancer, Liquid biopsy, MESSENGER-RNA, SERUM, MICRORNAS, EXPRESSION, CARCINOMA, PLASMA, TUMORIGENESIS, MORTALITY, PROTEIN, CA125

Downloads

  • published.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 1.28 MB

Citation

Please use this url to cite or link to this publication:

MLA
Hulstaert, Eva, et al. “Candidate RNA Biomarkers in Biofluids for Early Diagnosis of Ovarian Cancer : A Systematic Review.” GYNECOLOGIC ONCOLOGY, vol. 160, no. 2, 2021, pp. 633–42, doi:10.1016/j.ygyno.2020.11.018.
APA
Hulstaert, E., Morlion, A., Levanon, K., Vandesompele, J., & Mestdagh, P. (2021). Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer : a systematic review. GYNECOLOGIC ONCOLOGY, 160(2), 633–642. https://doi.org/10.1016/j.ygyno.2020.11.018
Chicago author-date
Hulstaert, Eva, Annelien Morlion, Keren Levanon, Jo Vandesompele, and Pieter Mestdagh. 2021. “Candidate RNA Biomarkers in Biofluids for Early Diagnosis of Ovarian Cancer : A Systematic Review.” GYNECOLOGIC ONCOLOGY 160 (2): 633–42. https://doi.org/10.1016/j.ygyno.2020.11.018.
Chicago author-date (all authors)
Hulstaert, Eva, Annelien Morlion, Keren Levanon, Jo Vandesompele, and Pieter Mestdagh. 2021. “Candidate RNA Biomarkers in Biofluids for Early Diagnosis of Ovarian Cancer : A Systematic Review.” GYNECOLOGIC ONCOLOGY 160 (2): 633–642. doi:10.1016/j.ygyno.2020.11.018.
Vancouver
1.
Hulstaert E, Morlion A, Levanon K, Vandesompele J, Mestdagh P. Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer : a systematic review. GYNECOLOGIC ONCOLOGY. 2021;160(2):633–42.
IEEE
[1]
E. Hulstaert, A. Morlion, K. Levanon, J. Vandesompele, and P. Mestdagh, “Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer : a systematic review,” GYNECOLOGIC ONCOLOGY, vol. 160, no. 2, pp. 633–642, 2021.
@article{8682919,
  abstract     = {{Ovarian cancer is often diagnosed in an advanced stage and is associated with a high mortality rate. It is assumed that early detection of ovarian cancer could improve patient outcomes. Unfortunately, effective screening methods for early diagnosis of ovarian cancer are still lacking. Extracellular RNAs circulating in human biofluids can reliably be measured and are emerging as potential biomarkers in cancer. In this systematic review, we present 75 RNA biomarkers detectable in human biofluids that have been studied for early diagnosis of ovarian cancer. The majority of these markers are microRNAs identified using RT-qPCR or microarrays in blood-based fluids. A handful of studies used RNA-sequencing and explored alternative fluids, such as urine and ascites. Candidate RNA biomarkers that were more abundant in biofluids of ovarian cancer patients compared to controls in at least two independent studies include miR-21, the miR-200 family, miR-205, miR-10a and miR-346. Amongst the markers confirmed to be lower in at least two studies are miR-122, miR-193a, miR-223, miR-126 and miR-106b. While these biomarkers show promising diagnostic potential, further validation is required before implementation in routine clinical care. Challenges related to biomarker validation and reflections on future perspectives to accelerate progress in this field are discussed.}},
  author       = {{Hulstaert, Eva and Morlion, Annelien and Levanon, Keren and Vandesompele, Jo and Mestdagh, Pieter}},
  issn         = {{0090-8258}},
  journal      = {{GYNECOLOGIC ONCOLOGY}},
  keywords     = {{Obstetrics and Gynaecology,Oncology,RNA,Transcriptomics,Diagnostic biomarkers,Ovarian cancer,Liquid biopsy,MESSENGER-RNA,SERUM,MICRORNAS,EXPRESSION,CARCINOMA,PLASMA,TUMORIGENESIS,MORTALITY,PROTEIN,CA125}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{633--642}},
  title        = {{Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer : a systematic review}},
  url          = {{http://dx.doi.org/10.1016/j.ygyno.2020.11.018}},
  volume       = {{160}},
  year         = {{2021}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: